BRPI0518484A2 - composiÇço, cÁpsula, e, processo para preparar a mesma - Google Patents

composiÇço, cÁpsula, e, processo para preparar a mesma

Info

Publication number
BRPI0518484A2
BRPI0518484A2 BRPI0518484-3A BRPI0518484A BRPI0518484A2 BR PI0518484 A2 BRPI0518484 A2 BR PI0518484A2 BR PI0518484 A BRPI0518484 A BR PI0518484A BR PI0518484 A2 BRPI0518484 A2 BR PI0518484A2
Authority
BR
Brazil
Prior art keywords
capsule
composition
surfactant
hlb
preparing same
Prior art date
Application number
BRPI0518484-3A
Other languages
English (en)
Inventor
Andrey V Peresypkin
Eleni Dokou
Craig Mckelvey
Charles Deluca
Laman L Alani
Todd Gibson
Danielle H Euler
Santipharp Panmai
W Peter Wuelfing
Thomas P Gandek
Drazen Ostovic
Timothy Rhodes
Brian K Hamilton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0518484A2 publication Critical patent/BRPI0518484A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇçO, CÁPSULA, E, PROCESSO PARA PREPARAR A MESMA. A N- [1S,2S]-3 -(4-clorofenil)-2-(3 -cianofenil)- 1 -metilpropil] - 2-metil-2- { [5 -trifluorometil]piridina-2-il } áxi } propanamida (Composto 1) melhorou surpreendentemente a solubilidade e a biodisponibilidade em um veículo lipofilico que compreende um óleo digerivel, farmaceuticamente aceitável, um tensoativo ou, um co-solvente ou, uma mistura de quaisquer de dois ou mais destes. Em uma forma de realização da presente invenção existe composições auto-emulsificantes ou auto-microemulsificantes que compreendem 1) Composto 1; 2) um tensoativo que tem um HLB de 1 a 8; e 3) um tensoativo que tem um HLB de mais de 8 a 20; e opcionalmente, 4) um óleo digerivel e/ou co-solvente e/ou antioxidante ou conservante.
BRPI0518484-3A 2004-11-24 2005-11-18 composiÇço, cÁpsula, e, processo para preparar a mesma BRPI0518484A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63074604P 2004-11-24 2004-11-24
PCT/US2005/041836 WO2006057903A2 (en) 2004-11-24 2005-11-18 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide

Publications (1)

Publication Number Publication Date
BRPI0518484A2 true BRPI0518484A2 (pt) 2008-11-18

Family

ID=36498432

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518484-3A BRPI0518484A2 (pt) 2004-11-24 2005-11-18 composiÇço, cÁpsula, e, processo para preparar a mesma

Country Status (14)

Country Link
US (1) US20070298099A1 (pt)
EP (1) EP1817012A2 (pt)
JP (1) JP2008521807A (pt)
KR (1) KR20070084531A (pt)
CN (1) CN101065115A (pt)
AU (1) AU2005309808A1 (pt)
BR (1) BRPI0518484A2 (pt)
CA (1) CA2587733A1 (pt)
IL (1) IL183309A0 (pt)
MX (1) MX2007006183A (pt)
NO (1) NO20073224L (pt)
RU (1) RU2007123366A (pt)
WO (1) WO2006057903A2 (pt)
ZA (1) ZA200703532B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184258A1 (en) * 2005-11-07 2016-06-30 Murty Pharmaceuticals, Inc. Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
AU2016203127B2 (en) * 2005-11-07 2018-07-12 Murty Pharmaceuticals, Inc An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
AU2007293393A1 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20090041839A1 (en) * 2007-05-23 2009-02-12 Beasley Martin W Pharmaceutical compositions for the treatment of pain
KR101493546B1 (ko) * 2007-08-21 2015-02-16 바실리어 파마슈티카 아게 항균 조성물
EP2548456B1 (en) * 2008-03-20 2015-07-08 Virun, Inc. Emulsions including a PEG-derivative of tocopherol
MX2010010214A (es) 2008-03-20 2010-12-21 Virun Inc Derivados de vitamina e y sus usos.
EP2111854A1 (en) * 2008-04-22 2009-10-28 Lek Pharmaceuticals D.D. Self-microemulsifying systems incorporated into liquid core microcapsules
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
US20100041622A1 (en) * 2008-08-13 2010-02-18 Bromley Philip J Compositions containing aminoalkanes and aminoalkane derivatives
WO2010044093A1 (en) * 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
WO2011041710A2 (en) * 2009-10-01 2011-04-07 Martek Biosciences Corporation Docosahexaenoic acid gel caps
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
CA2792330C (en) 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
JP2013209294A (ja) * 2010-07-30 2013-10-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 液状医薬組成物
EP2438911A1 (en) * 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
TWI640541B (zh) 2011-12-28 2018-11-11 中外製藥股份有限公司 Peptide compound having an annular portion and pharmaceutical composition thereof
CA2863544C (en) 2012-02-10 2019-03-26 Virun, Inc. Beverage compositions containing non-polar compounds
CN105007947B (zh) * 2013-01-14 2019-02-15 因佛斯特医疗有限公司 固溶体组合物及其在心血管疾病中的用途
RU2677346C2 (ru) * 2013-01-14 2019-01-16 ИнФерст Хэлткэр Лимитед Композиции и способы для лечения сильной боли
KR20150129664A (ko) * 2013-02-04 2015-11-20 인퍼스트 헬스케어 리미티드 만성 염증 및 염증성 질병을 치료하기 위한 조성물 및 방법
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
EP3157505B1 (en) * 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
US10799479B2 (en) 2015-04-10 2020-10-13 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
US10722527B2 (en) * 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
WO2018124162A1 (ja) * 2016-12-28 2018-07-05 中外製薬株式会社 化合物の膜透過性を改善するための自己乳化型製剤
MX390102B (es) * 2017-02-07 2025-03-20 Rhein Siegfried Sa De Cv Composicion de liberacion rapida de cinitaprida y simeticona y proceso para prepararla.
WO2018219804A1 (en) * 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
EP4487915A3 (en) * 2018-11-30 2025-03-19 ChemoCentryx, Inc. Capsule formulations
WO2020210723A1 (en) 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
WO2022251709A1 (en) * 2021-05-28 2022-12-01 Natural Extraction Systems, LLC Bioactive biphasic compositions
US20260102403A1 (en) * 2024-10-11 2026-04-16 Aligos Therapeutics, Inc. Oral formulations of thr-beta agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
CA2354233A1 (en) * 1998-12-11 2000-06-15 Pharmasolutions, Inc. Self-emulsifying compositions for drugs poorly soluble in water
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
FR2804015B1 (fr) * 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
US6562822B2 (en) * 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
DE10107261B4 (de) * 2001-02-16 2005-03-10 Merck Patent Gmbh Pharmazeutische Zusammensetzung
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
US8535716B2 (en) * 2004-04-01 2013-09-17 Tsrl, Inc. Methods and composition of extended delivery of water insoluble drugs
US20100216848A1 (en) * 2007-10-10 2010-08-26 Peresypkin Andrey V Liquid pharmaceutical compositions for parenteral administration of a substituted amide

Also Published As

Publication number Publication date
CN101065115A (zh) 2007-10-31
ZA200703532B (en) 2008-09-25
IL183309A0 (en) 2007-09-20
CA2587733A1 (en) 2006-06-01
EP1817012A2 (en) 2007-08-15
WO2006057903A2 (en) 2006-06-01
WO2006057903A3 (en) 2006-07-20
AU2005309808A1 (en) 2006-06-01
US20070298099A1 (en) 2007-12-27
NO20073224L (no) 2007-08-23
JP2008521807A (ja) 2008-06-26
MX2007006183A (es) 2007-09-11
RU2007123366A (ru) 2008-12-27
KR20070084531A (ko) 2007-08-24

Similar Documents

Publication Publication Date Title
WO2006057903A3 (en) Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US20200222360A1 (en) Stable cannabinoid compositions
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
JP2016523920A5 (pt)
CY1110261T1 (el) Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα
MX2014002362A (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
WO2020089891A1 (en) Topical minocycline foamable compositions
MX2022004735A (es) Composiciones que comprenden compuestos superfinos y su produccion.
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
AU2003285143A8 (en) Analysis of pharmaceutical solubility and stability
US8779000B1 (en) Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
JP4405151B2 (ja) カロテノイドを含む抗アテローム性動脈硬化組成物及びｌｄｌ酸化の抑制のための方法。
BRPI0511923A (pt) composições estabilizadas que compreendem um agente terapeuticamente ativo ácido cìtrico ou uma base conjugada e dioxido de cloro
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
AU2018296679A1 (en) Stable cannabinoid compositions
MY138172A (en) Pharmaceutical compositions based on azetidine derivatives
JP5855349B2 (ja) 油性製剤
US20090131496A1 (en) Pyrazolone derivative emulsion formulations
KR19980071702A (ko) 유제용 보존제 및 이를 함유한 유제
JP2019502735A (ja) 局所用薬剤を含むガレヌス製剤
AU2009316624B2 (en) Pyrazolone Derivative Formulations
JP2020502276A (ja) スルファサラジンおよびヒアルロン酸を含有する眼薬組成物
JP7412871B2 (ja) 外用組成物
MY140556A (en) Clear pharmaceutical aqueous microemulsion comprising propofol and process for preparation
JP2014516946A (ja) エザチオスタットとの賦形剤適合性

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.